Avant Technologies and Austrianova Launch Klothonova, Begin Developing Age Related Cellular Therapies Using 'Longevity Protein' Klotho

Rhea-AI Summary

Avant Technologies (OTCQB: AVAI) and Austrianova launched joint venture Klothonova on Oct 21, 2025 to develop cell‑based therapies that overexpress the longevity protein Klotho.

R&D proof‑of‑concept produced genetically modified human cells that overproduce Klotho and, when encapsulated in Austrianova’s Cell‑in‑Box, produced similar protein levels to non‑encapsulated cells. The JV is equally owned and will advance a GMP‑grade human cell clone toward preclinical and clinical studies; Austrianova is requalifying its ISO9001:2015 GMP isolator and preparing required documentation. The JV cites a cell therapy market projection of about $44 billion.

Positive

• Joint venture established with 50/50 ownership between Avant and SGAustria
• R&D proof‑of‑concept: genetically modified human cells overproduce Klotho
• Encapsulated cells produced similar Klotho levels to non‑encapsulated cells
• Austrianova preparing GMP isolator requalification (ISO9001:2015) for clinical grade production

Negative

• Program remains at R&D/preclinical transition; no clinical data or trial timelines disclosed
• Encapsulated cells in study described as non‑optimized, indicating further development required
• No commercial partnerships, revenue, pricing or explicit funding plans disclosed

LAS VEGAS, Oct. 21, 2025 /PRNewswire/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company") and global biotechnology firm, Austrianova, today announced the official launch of their joint venture, Klothonova LLC, and its groundbreaking Klotho development program. This initiative aims to engineer a genetically modified cell line that overexpresses the Klotho protein, paving the way for innovative cell-based therapies to combat age-related diseases such as Alzheimer's and cancer, while also advancing anti-aging and longevity treatments. By harnessing Austrianova's proprietary cell-encapsulation technology, Klothonova is positioning itself at the forefront of anti-aging biotechnology.

The program's initial phase has focused on R&D based proof of concept studies. A population of genetically modified human cells has been generated by Austrianova and shown to over-produce the Klotho protein. These cells were then successfully encapsulated in Austrianova's proprietary Cell-in-Box technology and shown to produce similar amounts of the Klotho protein to that produced by non-encapsulated cells. Although non-optimized, the encapsulated cells used in the study demonstrate quite clearly the feasibility of using encapsulated cells to continuously produce the Klotho protein.

The next stage for the program is to move forward with a proprietary GMP grade human cell clone that will be used in preclinical and eventually clinical studies. In preparation for this next stage, Austrianova is conducting routine servicing and requalification on its already ISO9001:2015 compliant, state of the art GMP isolator and facility, and preparing the necessary documentation needed for the next steps of the program. These essential steps will ensure the reproducibility and safety of the Klotho protein-producing cell lines, laying a strong foundation for producing high-quality clinical-grade therapeutics.

"The R&D level proof of concept study provides a clear rationale for the program, giving a green light to move to GMP studies. In addition, the meticulous preparations of the GMP facility at Austrianova represent a foundational milestone in bringing Klotho-based therapies to patients who need them most," said Chris Winter, CEO of Avant Technologies. "By prioritizing GMP compliance from the outset, Klothonova is committed to delivering safe, effective treatments that could transform the landscape of age-related disease management."

Dr. Brian Salmons, CEO of Austrianova, added, "Once again our encapsulation technology has proven it is ideal for long term continuous production of yet another protein, in this case, Klotho. Our expertise in cell encapsulation combined with Avant's innovative vision makes this joint venture uniquely positioned for success. The preparations we are undertaking today ensure that every cell we produce meets the highest standards of quality and safety, accelerating our path toward clinical trials."

This development program builds on the joint venture agreement signed in September 2025, which established Klothonova as a Nevada-based entity equally owned by Avant and Austrianova's affiliate, SGAustria Pte. Ltd.  The JV's focus on Klotho - a protein renowned for its anti-aging and protective effects on organs - aligns with growing market demand for cellbased therapies, projected to reach $44 billion globally¹.

1. https://www.biospace.com/press - releases/cell - therapy - market - size - uplifts - usd - 44 - 39 - bn - at - 22 https://www.biospace.com/press-releases/cell-therapy-market-size-uplifts-usd-44-39-bn-at-22-69-healthy-cagr-by-2034 69 - healthy - cagr - by - 2034  

About Avant Technologies Inc.
Avant Technologies Inc. is dedicated to advancing health through strategic biotech partnerships, focusing on innovative cell-based therapies to combat chronic and age-related diseases and promote longevity.

About Austrianova (SGAustria Pte. Ltd.) 
Austrianova, based in Singapore, is a leading biotechnology company specializing in cell encapsulation, GMP-grade cell products, and cell line development, backed by over 50 peer reviewed publications and partnerships with global pharmaceutical and biotech companies. 

More information about Avant can be found at https://avanttechnologies.com 

You can also follow us on social media at:

https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai  
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI  

Forward-Looking Statements 
Certain statements contained in this press release may constitute "forward-looking statements."  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact.  Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.

Contact: 
Avant Technologies Inc.
info@avanttechnologies.com

Logo - https://mma.prnewswire.com/media/2370694/5574100/Avant_Technologies.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/avant-technologies-and-austrianova-launch-klothonova-begin-developing-age-related-cellular-therapies-using-longevity-protein-klotho-302589994.html

SOURCE Avant Technologies Inc.

FAQ

What did Avant (AVAI) and Austrianova announce on October 21, 2025?

They launched Klothonova, a 50/50 joint venture to develop Klotho‑overexpressing cell therapies and advance a GMP cell clone toward preclinical and clinical studies.

What evidence supports Klothonova's Klotho program for AVAI?

An R&D proof‑of‑concept produced genetically modified human cells that overproduce Klotho and encapsulated cells produced similar protein levels to non‑encapsulated cells.

What are the next steps and timelines for AVAI's Klothonova program?

Next steps are advancing a proprietary GMP‑grade human cell clone into preclinical and eventually clinical studies; no trial dates were disclosed.

How is Austrianova preparing to support AVAI's clinical work for Klothonova?

Austrianova is requalifying its state‑of‑the‑art GMP isolator (ISO9001:2015) and preparing required documentation for clinical‑grade production.

Does the Klothonova announcement include commercial revenue or funding details for AVAI (AVAI)?

No—there are no commercial agreements, revenue figures, or explicit funding plans disclosed in the announcement.